Cargando…

Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence

The first case of SARS-CoV-2 infection was reported in December 2019. Due to the rapid spread of the disease and the lack of adequate therapy, the use of plants that have a long history in the treatment of viral infections has often been considered. The aim of this paper is to provide a brief review...

Descripción completa

Detalles Bibliográficos
Autores principales: Bijelić, Katarina, Hitl, Maja, Kladar, Nebojša
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686831/
https://www.ncbi.nlm.nih.gov/pubmed/36421257
http://dx.doi.org/10.3390/antibiotics11111614
_version_ 1784835851393433600
author Bijelić, Katarina
Hitl, Maja
Kladar, Nebojša
author_facet Bijelić, Katarina
Hitl, Maja
Kladar, Nebojša
author_sort Bijelić, Katarina
collection PubMed
description The first case of SARS-CoV-2 infection was reported in December 2019. Due to the rapid spread of the disease and the lack of adequate therapy, the use of plants that have a long history in the treatment of viral infections has often been considered. The aim of this paper is to provide a brief review of the literature on the use of phytochemicals during the new pandemic. An extensive search of published works was performed through platforms Google Scholar, PubMed, Science Direct, Web of Science and Clinicaltrials.gov. Numerous preclinical studies on the use of phytochemicals (quercetin, curcumin, baicalin, kaempferol, resveratrol, glycyrrhizin, lycorine, colchicine) against SARS-CoV-2 have shown that these components can be effective in the prevention and treatment of this infection. Clinical research has proven that the use of black cumin and green propolis as well as quercetin has positive effects. As for other phytochemicals, in addition to preclinical testing which has already been carried out, it would be necessary to conduct clinical tests in order to assert their effectiveness. For those phytochemicals whose clinical efficacy has been proven, it would be necessary to conduct research on a larger number of patients, so that the conclusions are more representative.
format Online
Article
Text
id pubmed-9686831
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96868312022-11-25 Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence Bijelić, Katarina Hitl, Maja Kladar, Nebojša Antibiotics (Basel) Review The first case of SARS-CoV-2 infection was reported in December 2019. Due to the rapid spread of the disease and the lack of adequate therapy, the use of plants that have a long history in the treatment of viral infections has often been considered. The aim of this paper is to provide a brief review of the literature on the use of phytochemicals during the new pandemic. An extensive search of published works was performed through platforms Google Scholar, PubMed, Science Direct, Web of Science and Clinicaltrials.gov. Numerous preclinical studies on the use of phytochemicals (quercetin, curcumin, baicalin, kaempferol, resveratrol, glycyrrhizin, lycorine, colchicine) against SARS-CoV-2 have shown that these components can be effective in the prevention and treatment of this infection. Clinical research has proven that the use of black cumin and green propolis as well as quercetin has positive effects. As for other phytochemicals, in addition to preclinical testing which has already been carried out, it would be necessary to conduct clinical tests in order to assert their effectiveness. For those phytochemicals whose clinical efficacy has been proven, it would be necessary to conduct research on a larger number of patients, so that the conclusions are more representative. MDPI 2022-11-13 /pmc/articles/PMC9686831/ /pubmed/36421257 http://dx.doi.org/10.3390/antibiotics11111614 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bijelić, Katarina
Hitl, Maja
Kladar, Nebojša
Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
title Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
title_full Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
title_fullStr Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
title_full_unstemmed Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
title_short Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
title_sort phytochemicals in the prevention and treatment of sars-cov-2—clinical evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686831/
https://www.ncbi.nlm.nih.gov/pubmed/36421257
http://dx.doi.org/10.3390/antibiotics11111614
work_keys_str_mv AT bijelickatarina phytochemicalsinthepreventionandtreatmentofsarscov2clinicalevidence
AT hitlmaja phytochemicalsinthepreventionandtreatmentofsarscov2clinicalevidence
AT kladarnebojsa phytochemicalsinthepreventionandtreatmentofsarscov2clinicalevidence